ICP-022
Phase 2Small molecule
ICP-022 is one of 24 small molecule programs targeting Central Nervous System Lymphoma. It is currently in Phase 2.
2
Indications
11
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
27 competitors in Central Nervous System Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Tepadina
Jazz PharmaceuticalsApproved
Idamycin
PfizerApproved
Brukinsa
BBeOne Medicines
Approved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Trexall
Jazz PharmaceuticalsPhase 2
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Fludara
SanofiPhase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Alimta
SShawn Eagle
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Waldenstrom macroglobulinemia1 trial
Treatment1 trial
Systemic Lupus Erythematosus1 trial
6 more indications
Central Nervous System Lymphoma1 trial
Mantle Cell Lymphoma1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ICP-022. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details